投稿日：2026.4.3／更新日：2026.4.3
A Global Leader in Precision Immuno-Oncology
As the first medical institution in the world to introduce WT1 dendritic cell vaccine therapy into clinical practice, Precision Clinic Group has built one of the world’s leading clinical platforms in dendritic cell vaccine therapy. Today, we advance this legacy through SynerTri Immunotherapy—our integrated precision strategy for patients with advanced cancer.
What began as a breakthrough in dendritic cell vaccine technology has evolved into a comprehensive precision platform tailored to each patient’s unique tumor biology. We do not simply activate the immune system—we design a strategic treatment environment in which anti-cancer immunity can function more effectively within the body.
One of the world’s leading clinical records in dendritic cell vaccine therapy.
Built on technology developed at The Institute of Medical Science, The University of Tokyo (IMSUT), and advanced through the WT1 platform developed at Osaka University and Hokkaido University.
The first medical institution to launch WT1 dendritic cell vaccine therapy worldwide.
Our clinical platform is rooted in advanced dendritic cell culture technology developed at The Institute of Medical Science, The University of Tokyo. By integrating the WT1 platform developed at Osaka University and Hokkaido University, we enabled the first global
clinical application of WT1 dendritic cell vaccine therapy.
Precision Clinic Group does not simply offer another immunotherapy program. We represent the continuation of a decades-long clinical and scientific evolution. With over 6,500 treated cases, our experience places us among the world’s leading clinical groups in this field, underpinning a treatment platform shaped by decades of rigorous development and patient-centered care.
Our platform has evolved beyond shared antigens alone. While WT1 remains a cornerstone, our strategy now incorporates Tumor-Associated Antigens (TAAs), Neoantigens, and autologous tumor tissue–derived antigens, depending on the specific biology of each patient’s cancer.
Using each patient’s unique genomic information, we identify specific neoantigen targets and design custom neoantigen-based dendritic cell vaccines when appropriate.
This allows us to move from generalized antigen targeting toward a truly individualized precision
immunotherapy platform.
SynerTri Immunotherapy is our original integrated cancer treatment strategy.
It is a coordinated therapeutic design built around three key functions of anti-cancer immune
activation:
|
Component |
Role |
Mechanism |
|
The Accelerator |
Dendritic Cell Vaccine Therapy |
Teaches the immune system what to attack, including WT1, TAAs, neoantigens, and autologous tumor tissue–derived antigens. |
|
The Brake Release |
Immune Checkpoint Inhibitors |
Releases immune suppression pathways—such as PD-1, PD-L1, and CTLA-4—that tumors use to evade the immune system. |
|
The Switch |
Local Tumor-Directed Therapy |
Uses radiation therapy, particle therapy, BNCT, or cryotherapy to generate the biological signals needed to awaken anti-cancer immunity. |
SynerTri is not a single drug or a single procedure. It is a strategic, three-component platform designed to ensure that anti-cancer immunity functions effectively within the tumor microenvironment.
We believe cancer treatment must be designed around the molecular and immunological characteristics of each patient’s tumor.
By integrating genomic information with immunotherapy and local treatment, we move beyond general immune activation toward a strategy that is specific to the biology of the individual cancer.
Our process is designed for precision at every step:
Tailoring the strategy to your unique tumor profile.
A process to collect immune cells from your blood, used for vaccine production.
Preparing your personalized dendritic cell vaccine.
Treatment is administered once every 1–3 weeks, with an initial course of 7 sessions over approximately four months.
For neoantigen-based vaccines, the preparation phase—including genomic
analysis—typically requires 2–3 months before administration begins.
Precision Clinic Group pioneered WT1 dendritic cell vaccine therapy. Today, that legacy has evolved into SynerTri Immunotherapy.
This history defines our direction: from early innovation and WT1 clinical leadership to a
broader precision platform that incorporates neoantigen-guided design and integrated
immune strategies.
Precision Clinic Group welcomes patients from around the world. We offer dedicated support
for overseas patients, including second-opinion consultations to discuss treatment options,
feasibility, timing, and customized planning.
To learn more about SynerTri Immunotherapy and discuss whether this approach may be appropriate for your case, please contact our international team.
▶︎▶︎▶︎Request an International Consultation
An integrated three-component strategy combining dendritic cell vaccine therapy, immune
checkpoint inhibitors, and local tumor-directed therapy.
It coordinates the vaccine with other treatments to ensure the immune system can strike the
tumor effectively.
Yes. WT1 remains a core component and a key antigen within the SynerTri framework.
Yes. Custom-designed neoantigen approaches are utilized based on detailed genomic
analysis.
Preparation varies; for neoantigen-based vaccines, analysis and manufacturing typically take
2–3 months.
